Loading...
•
Dec 31, 2019
Celcuity Q4 2019 Earnings Report
Celcuity reported a net loss for the fourth quarter and full year 2019, while making progress in advancing its CELsignia platform and expanding its Scientific Advisory Board.
Key Takeaways
Celcuity reported a net loss of $1.81 million, or $0.18 per share, for the fourth quarter of 2019. The company made significant progress advancing its CELsignia platform and expanded its Scientific Advisory Board.
Presented results from pre-clinical studies for new CELsignia PI3K Test at the San Antonio Breast Cancer Symposium.
Began discussions with leading cancer centers to design clinical trials evaluating PI3K targeted therapies in HER2-negative breast cancer patients identified by the CELsignia PI3K Test.
Advanced development of a fourth test for breast cancer, with pre-clinical studies expected to be completed in 2020.
Announced pre-clinical study results for first CELsignia test for ovarian cancer at the 2020 Annual Meeting of the American Association for Cancer Research.
Celcuity
Celcuity
Forward Guidance
Celcuity expects interim results from the FACT 1 trial in early-to-mid-2021 and final results approximately nine months later. Interim results from the FACT 2 trial are expected in mid-2021 and final results approximately 9-12 months later.